La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Quince Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Quince Therapeutics..

Quince Therapeutics (NASDAQ:QNCX) Azioni, Catena delle Opzioni

Quince Therapeutics

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Quince Therapeutics Inc

WIIM

Salesforce shares are trading higher after the company announced it will hire 1,000 people for an "AI product sales push" and is also developing artificial intelligence agents.

<p>Merck (NYSE:&nbsp;MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR&#xAE; (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.</p>
<p>Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in PAH patients.</p>


News

Global

Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II Or III

Gray Television shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, the company said it's carefully evaluating capital expenditure needs for 2025 and announced its board approved an increase in its debt repurchase authorization.

<p>TD Cowen  analyst Andrew Charles   maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Hold and raises the price target from $18 to $21.</p>


Price Target

Analyst Ratings

FWRG

TD Cowen Maintains Hold on First Watch Restaurant Gr, Raises Price Target to $21

DVAX

Dynavax Technologies shares are trading higher after the company reported better-than-expected Q3 EPS results and launched a $200 million share buyback program. HC Wainwright & Co. reiterated a Buy rating on the stock.

<p>Benchmark  analyst Robert Wasserman   maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and raises the price target from $110 to $135.</p>


LGND

Benchmark Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $135

<p><a href="https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push" title="https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push">https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push</a></p>
<p>&nbsp;</p>
<p>Salesforce Inc. plans to hire more than 1,000 workers to sell its new generative AI agent product.&nbsp;</p>


Management

"Salesforce To Hire 1,000 People For AI Product Sales Push; Company To Take Advantage Of AI 'Momentum,' CEO Says; Rivals Also Developing Artificial Intelligence Agents" - Bloomberg News

<p>HC Wainwright &amp; Co.  analyst Emily Bodnar   maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy and raises the price target from $95 to $115.</p>


ACLX

HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $115

<p><strong>We revise our guidance</strong></p>
<p>Due to higher-than-expected inflation in the second half of the year, we have revised our year-end inflation forecast upwards. Accordingly, we are updating our revenue growth target5 for 2024 to approximately 7%. We maintain our EBITDA margin expectation at approximately 42% and our operational capex to sales6 ratio target at approximately 23%.</p>
<p>I extend my heartfelt thanks to all our employees for their contributions to our success and express my gratitude to our Board of Directors for their continued support.</p>
<p>(1) EBITDA is a non-GAAP financial measure. See page 14 for the explanation of how we calculate Adjusted EBITDA and its reconciliation to net income<br /><br />(2) Excluding M2M<br /><br />(3) Following the change in organizational structure, the revenues of Turkcell Sigorta Aracılık Hizmetleri A.Ş. (Insurance Agency), which was previously managed under Financell, are now classified as "Other" in the Techfin segment as of the first quarter of 2023.<br /><br />(4) Including IPTV, OTT TV, fizy, lifebox and GAME+<br /><br />(5) Our expectations for 2024 incorporate the effects of inflation accounting under IAS 29. These projections are based on assumptions regarding factors beyond our control, including key macroeconomic indicators such as inflation. Specifically, we are assuming an annual inflation rate of 43%, applied on a monthly basis, (previous estimate: 37%). This paragraph contains forward-looking statements that reflect our current estimates and expectations regarding market conditions across all of our businesses. However, there can be no assurance that these forward-looking statements will occur as anticipated. For a discussion of the various factors that could impact the outcome of these forward-looking statements, please refer to our 2023 annual report on Form 20-F filed with the SEC, specifically the risk factors section.<br /><br />(6) Excluding license fees</p>


Guidance

Turkcell Iletisim Hizmetleri On Thursday November 7, 2024 Said Due To Higher-Than-Expected Inflation In The 2H Of The Year, Have Revised Our Year-End Inflation Forecast Upwards; Updating Our Revenue Growth Target For 2024 To ~ 7%. We Maintain Our EBITDA Margin Expectation At ~ 42% And Our Operational CapEx To Sales Ratio Target At ~ 23%

<p>Needham  analyst James Ricchiuti   maintains nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) with a Buy and raises the price target from $15 to $16.</p>


LASR

Needham Maintains Buy on nLight, Raises Price Target to $16

<p>Deep-pocketed investors have adopted a bearish approach towards Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AAPL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 27 extraordinary options activities for Apple. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 48% bearish. Among these notable options, 8 are puts, totaling $387,928, and 19 are calls, amounting to $1,239,539.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $240.0 for Apple, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Apple's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apple's whale trades within a strike price range from $100.0 to $240.0 in the last 30 days. </p>
<h3>Apple 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094737_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.45</td>
<td>$7.35</td>
<td>$7.45</td>
<td>$230.00</td>
<td>$312.0K</td>
<td>30.6K</td>
<td>487</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.0</td>
<td>$129.6</td>
<td>$130.0</td>
<td>$100.00</td>
<td>$117.0K</td>
<td>489</td>
<td>24</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$3.5</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$225.00</td>
<td>$100.5K</td>
<td>12.0K</td>
<td>948</td>
</tr>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$5.15</td>
<td>$5.05</td>
<td>$5.1</td>
<td>$230.00</td>
<td>$91.7K</td>
<td>972</td>
<td>189</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.09</td>
<td>$2.08</td>
<td>$2.08</td>
<td>$227.50</td>
<td>$83.3K</td>
<td>7.5K</td>
<td>8.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Apple</h3>
<p>Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.</p>
<h3>Current Position of Apple</h3>
<ul>
<li>With a trading volume of 14,296,721, the price of AAPL is down by -0.18%, reaching $227.07.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Apple</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $224.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has decided to maintain their Underweight rating on Apple, which currently sits at a price target of $184.<br />
&#x2A; An analyst from Keybanc has revised its rating downward to Underweight, adjusting the price target to $200.<br />
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Apple, which currently sits at a price target of $262.<br />
&#x2A; An analyst from Maxim Group persists with their Hold rating on Apple, maintaining a target price of $215.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $260. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apple options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

AAPL

What the Options Market Tells Us About Apple

<p>6 analysts have shared their evaluations of OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated OrthoPediatrics and provided 12-month price targets. The average target is $39.67, accompanied by a high estimate of $50.00 and a low estimate of $28.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.82%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094736_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of OrthoPediatrics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OrthoPediatrics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of OrthoPediatrics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into OrthoPediatrics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on OrthoPediatrics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind OrthoPediatrics</h2>
<p>OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.</p>
<h3>Understanding the Numbers: OrthoPediatrics's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining OrthoPediatrics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.35%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> OrthoPediatrics's net margin excels beyond industry benchmarks, reaching <strong>-14.51%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> OrthoPediatrics's ROE excels beyond industry benchmarks, reaching <strong>-2.13%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.72%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> OrthoPediatrics's debt-to-equity ratio is below the industry average at <strong>0.2</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


KIDS

The Latest Analyst Ratings For OrthoPediatrics

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>GE Vernova</strong>.</p>
<p>Looking at options history for GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 38% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $303,024 and 11, calls, for a total amount of $1,151,800.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $345.0 for GE Vernova over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for GE Vernova's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GE Vernova's whale trades within a strike price range from $150.0 to $345.0 in the last 30 days. </p>
<h3>GE Vernova 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094732_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$91.0</td>
<td>$89.0</td>
<td>$91.0</td>
<td>$250.00</td>
<td>$364.0K</td>
<td align="right">309</td>
<td align="right">40</td>
</tr>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$20.7</td>
<td>$20.5</td>
<td>$20.5</td>
<td>$340.00</td>
<td>$207.0K</td>
<td align="right">4</td>
<td align="right">101</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$310.00</td>
<td>$206.0K</td>
<td align="right">16</td>
<td align="right">40</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$60.0</td>
<td>$59.0</td>
<td>$60.0</td>
<td>$300.00</td>
<td>$198.0K</td>
<td align="right">199</td>
<td align="right">33</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$70.9</td>
<td>$69.2</td>
<td>$69.2</td>
<td>$300.00</td>
<td>$138.4K</td>
<td align="right">59</td>
<td align="right">21</td>
</tr>
</tbody>
</table>
</p>
<h3>About GE Vernova</h3>
<p>GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.</p>
<p>Following our analysis of the options activities associated with GE Vernova, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is GE Vernova Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,430,176, with GEV's price down by -0.32%, positioned at $335.24.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 11 days.</li>
</ul>
<h3>Expert Opinions on GE Vernova</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $307.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on GE Vernova with a target price of $308.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on GE Vernova, which currently sits at a price target of $285.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on GE Vernova, maintaining a target price of $301.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on GE Vernova with a target price of $325.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on GE Vernova, maintaining a target price of $320. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest GE Vernova options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With GEV

<p>Deep-pocketed investors have adopted a bullish approach towards Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SPOT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for Spotify Technology. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 47% leaning bullish and 39% bearish. Among these notable options, 3 are puts, totaling $239,975, and 20 are calls, amounting to $1,741,376.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $380.0 to $465.0 for Spotify Technology over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Spotify Technology's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Spotify Technology's whale activity within a strike price range from $380.0 to $465.0 in the last 30 days. </p>
<h3>Spotify Technology Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094727_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$32.35</td>
<td>$30.55</td>
<td>$31.4</td>
<td>$390.00</td>
<td>$178.9K</td>
<td>4.4K</td>
<td align="right">260</td>
</tr>
<tr>
<td>SPOT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$24.0</td>
<td>$23.1</td>
<td>$23.8</td>
<td>$410.00</td>
<td>$178.5K</td>
<td>15</td>
<td align="right">75</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$32.55</td>
<td>$30.55</td>
<td>$31.4</td>
<td>$390.00</td>
<td>$175.8K</td>
<td>4.4K</td>
<td align="right">165</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$32.05</td>
<td>$30.6</td>
<td>$31.75</td>
<td>$390.00</td>
<td>$161.9K</td>
<td>4.4K</td>
<td align="right">400</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$32.15</td>
<td>$30.55</td>
<td>$31.7</td>
<td>$390.00</td>
<td>$148.9K</td>
<td>4.4K</td>
<td align="right">349</td>
</tr>
</tbody>
</table>
</p>
<h3>About Spotify Technology</h3>
<p>Spotify is the leading global music streaming service provider, with over 600 million monthly active users and 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.</p>
<p>Having examined the options trading patterns of Spotify Technology, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Spotify Technology Standing Right Now?</h3>
<ul>
<li>With a trading volume of 798,576, the price of SPOT is up by 0.58%, reaching $402.17.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 4 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Spotify Technology</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $453.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Spotify Technology, targeting a price of $470.<br />
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Spotify Technology, which currently sits at a price target of $490.<br />
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Spotify Technology, which currently sits at a price target of $438.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Spotify Technology, which currently sits at a price target of $430.<br />
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Buy rating on Spotify Technology with a target price of $440. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Spotify Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


SPOT

Looking At Spotify Technology's Recent Unusual Options Activity

<p>Benchmark  analyst Cody Acree   reiterates Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and maintains $9 price target.</p>


Reiteration

INDI

Benchmark Reiterates Buy on Indie Semiconductor, Maintains $9 Price Target

<p><strong>Pinterest, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) stock is moving lower Friday after the company reported worse-than-expected <a href="https://www.benzinga.com//node/41827920">third-quarter earnings. </a></p>
<p><strong>What To Know:</strong> Pinterest stock fell approximately 12% after the bell on Thursday following the earnings report and continues to trade lower on Friday.</p>
<p>The company reported earnings per share of 4 cents missing analyst estimates of 7 cents. In addition, it reported sales of $898 million beating analyst estimates of $896.34 million. </p>
<p>Pinterest provided a more detailed look into its revenue. It reported revenue of $719 million from the U.S. and Canada, $137 million from Europe and $42 million from the rest of the world.</p>
<p>The company also reported some important business metrics. Pinterest announced Average Revenue Per User (ARPU) of $1.70 and Global Monthly Active Users (MAUs) of 537 million. </p>
<p>&#8220;Our AI investments are driving results by powering better personalized experiences and greater performance for advertisers, with our lower-funnel ad tools being the fastest-growing part of our business. Advertisers are increasingly relying on Pinterest to engage our growing audience who see us as a great place to find inspiration, curate and shop,&#8221; said CEO of Pinterest <strong>Bill Ready</strong>.</p>
<p>Pinterest issued guidance for the 2024 fourth-quarter, which may be weighing on the stock. It anticipates revenue between $1.12 billion and $1.14 billion versus analyst estimates of $1.14 billion.</p>
<p><strong>Analyst Changes:</strong> Following the earnings report, multiple analysts issued <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/41850902/pinterest-reports-healthy-q3-q4-guidance-disappoints-6-analysts-cut-forecasts-while-looking-for-ai-to-drive-1h25">price target changes.</a></p>
<p><strong>Related Link: <a href="https://www.benzinga.com/markets/equities/24/11/41795194/cathie-woods-wednesday-exodus-moderna-and-jack-dorseys-block-stocks-get-dumped">Cathie Wood&#8217;s Wednesday Exodus: Moderna And Jack Dorsey&#8217;s Block Stocks Get Dumped</a></strong></p>
<p><strong>PINS Price Action:</strong> At the time of publication, Pinterest stock is moving 15.9% lower at $28.55, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Image via Shutterstock</em></p>


Movers

PINS

What's Going On With Pinterest Shares Friday?

<p>The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve&#8217;s interest rate cuts in September. </p>
<p>According to GlobalData, the top 20 global biopharmaceutical companies <a href="https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/#:~:text=As%20a%20result%2C%20the%20top,data%20analytics%20and%20research%20company.">saw</a> a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. </p>
<p>This rebound highlights the industry&#8217;s potential for growth despite challenges earlier in the year.</p>
<p><strong>Bristol-Myers Squibb &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by advancements in its pipeline, notably the FDA&#8217;s approval of its antipsychotic drug, Cobenfy, for treating <a href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea">schizophrenia in September 2024</a>. </p>
<p><strong>Gilead Sciences Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost">posted impressive growth</a>, rising 22.1% in market value, thanks to the accelerated FDA approval of Livdelzi, a treatment for <a href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal">primary biliary cholangitis</a>, as well as the approval of its antibody-drug conjugate, Trodelvy, for HR-/HER2- breast cancer in Japan.</p>
<p><strong>Sanofi SA</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) experienced a 19.2% jump in market capitalization, largely fueled by its <a href="https://www.benzinga.com/general/biotech/24/10/41541274/sanofi-earns-5b-q3-core-profit-on-strong-dupixent-and-vaccine-sales-raises-2024-forecast">flagship drug Dupixent</a>. The drug&#8217;s strong performance in the treatment of conditions such as asthma and atopic dermatitis, coupled with its recent EMA and FDA approvals for chronic obstructive pulmonary disease (COPD), further <a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease">boosted Sanofi&#8217;s standing</a>. </p>
<p>Similarly, <strong>AbbVie Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) saw a 15.2% increase in its market cap, driven by the continued success of its immunology drugs—Humira, Skyrizi, and Rinvoq—which together generated nearly $7 billion <a href="https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and">in Q2 2024 sales</a>.</p>
<p><strong>Alnylam Pharmaceuticals Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) joined the top 20 biopharmaceutical companies with a 14.9% rise in its market value, following its RNAi drug vutrisiran's positive results in treating ATTR <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">amyloidosis with cardiomyopathy</a>. </p>
<p><strong>Roche Holdings AG's </strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) market capitalization grew by 13.8%, spurred by the FDA&#8217;s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, the latter being the only approved subcutaneous <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">PD-L1 inhibitor available</a>.</p>
<p>On the downside, Wegovy maker <strong>Novo Nordisk A/S</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw an 18.2% drop in its market cap after the FDA rejected its BLA filing for the once-<a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">weekly insulin icodec</a>.</p>
<p>Similarly, <strong>Eli Lilly &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported a slight decline of 2.1%, though both companies retained their leadership in diabetes and <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">weight loss drugs</a>. </p>
<p><strong>Merck &amp; Co Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) also faced a 8.2% fall in market value, largely due to disappointing sales of its HPV vaccine, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-">Gardasil, in China</a>.</p>
<p>&nbsp;"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such as Gilead Sciences and Bristol-Myers Squibb,&#8221; says GlobalData analyst.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41853302/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-heres-why"><strong>ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why</strong></a></li>
</ul>
<p><em>Image Via Shutterstock</em></p>


Biotech

Large Cap

Health Care

Trading Ideas

General

ABBV

ALNY

GILD

RHHBY

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

<p>The cannabis market is facing heightened volatility <a href="https://www.benzinga.com/markets/cannabis/24/11/41782344/tilray-trulieve-and-other-cannabis-stocks-nosediving-as-industry-faces-new-wave-of-political-unc">post-election</a> as investor concerns mount over political uncertainty and the fallout from Florida's <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">failed legalization vote</a>, leading to significant selloffs in top U.S. and Canadian cannabis stocks. Adult-use legalization was also <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">rejected</a> in North Dakota and South Dakota.</p>
<p>Given this setup, investors might be asking: was the post-elections selloff an overreaction or a rational market adjustment?</p>
<p>Experts analysts from <strong>Viridian Capital Advisors</strong> weighed in on the debate.</p>
<h3 class="wp-block-heading">Market Meltdown: Was The Sell-Off Justified?</h3>
<p>In the wake of Florida&#8217;s failed ballot vote for adult-use cannabis, the market cap of 31 publicly traded cannabis companies fell by $2.6 billion from Friday, November 1 to Wednesday, November 6.</p>
<p>Florida&#8217;s medical cannabis market alone is projected to reach $2.1 billion in sales by 2024. </p>
<p>If adult-use legalization had passed, it could have effectively doubled sales, adding another $2.1 billion. </p>
<p>Applying a conservative 30% EBITDA margin to these potential sales would yield an EBITDA loss of $630 million. </p>
<p>Using a 5x multiple, also considered conservative, the projected decline in market cap would be around $3.15 billion — suggesting that the $2.6 billion markdown might<strong> </strong>not have been as exaggerated as it seems.</p>
<p>However, there's a caveat: not all companies on the list have operations in Florida, though 81% of the market cap is held by firms actively operating there. </p>
<p>A greater concern is the broader impact on the industry's growth narrative.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">Cannabis Reform Stumbles In 2024 Elections: A State-By-State Breakdown As Stocks Take A Hit</a></strong></p>
<h3 class="wp-block-heading"><strong>Some Earnings Added Pessimism</strong></h3>
<p>For <a href="https://www.benzinga.com/author/viridian-capital-advisors">Viridian Capital Advisors</a>, in addition to the disappointing ballot results, earnings reports from major players including Trulieve (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>), TerrAscend (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>), Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), <a href="https://www.benzinga.com/markets/cannabis/24/11/41808095/the-cannabist-co-q3-revenue-declines-8-completes-5m-asset-sale-exits-florida-market-amid-restruc">Cannabist</a> (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTCQX">CBSTF</a>) and GTI (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>)<em> </em>have compounded concerns.</p>
<p>The results revealed significant misses, even against lowered expectations. </p>
<p>Aggregate revenues for these companies are projected to be down 0.4% year-over-year and 1.1% sequentially. The<strong> </strong>decline in EBITDA is 2.2% year-over-year and 4.2% sequentially.</p>
<p>The failed vote has undeniably stretched the industry's growth timeline, leaving investors to weigh <a href="https://www.benzinga.com/markets/cannabis/24/11/41823267/cannabis-stocks-is-it-time-to-buy-the-dip-after-elections-and-legalization-setbacks">potential catalysts </a>against a stark present reality.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/government/regulations/24/11/41851368/hemp-market-surge-how-new-regulations-could-impact-growth">Hemp Market Surge: How New Regulations Could Impact Growth</a></strong></li>
</ul>
<p><em>Cover: AI generated image</em></p>


Cannabis

Economics

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

TRSSF

Cannabis Stocks Plunged After Florida Legalization Failed: Rational Reaction Or Market Overreach?

<p><strong>CarGurus, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) reported better-than-expected third-quarter financial results and <a href="https://www.benzinga.com/quote/carg/earnings">issued FY24 guidance EPS guidance above estimates.</a></p>
<p>CarGurus reported quarterly earnings of 45 cents per share which beat the analyst consensus estimate of 42 cents. The company reported quarterly sales of $231.358 million which beat the analyst consensus estimate of $223.537 million.</p>
<p>&#8220;We are proud of our third quarter results as our Marketplace revenue growth further accelerated, and we leveraged our cost base to drive operating efficiencies,&#8221; said Jason Trevisan, Chief Executive Officer at CarGurus. &#8220;Our customer-centric focus has enabled us to capture greater wallet share, as we strive to continuously enhance the value proposition we offer to our dealer partners, delivering actionable insights, tools, and functionalities that will over time drive adoption, engagement, and retention across our platform.&#8221;  </p>
<p>CarGurus said it sees FY2024 adjusted EPS of $1.67 to 1.73 versus estimates of $1.64. The company sees sales of $885.000 million-905.000 million vs $883.61 million.</p>
<p>CarGurus shares gained 4.9% to trade at $35.00 on Friday.</p>
<p>These analysts made changes to their price targets on CarGurus following earnings announcement.</p>
<ul>
<li>Oppenheimer analyst Jed Kelly maintained CarGurus with an Outperform and raised the price target from $32 to $44.</li>
<li>DA Davidson analyst Tom White maintained CarGurus with a Neutral and raised the price target from $26.5 to $38.5.</li>
<li>JP Morgan analyst Rajat Gupta maintained the stock with an Overweight and raised the price target from $36 to $40.</li>
<li>Needham analyst Chris Pierce maintained CarGurus with a Buy and raised the price target from $27 to $39.</li>
</ul>
<p><strong>Considering buying RL stock? Here&#8217;s what analysts think:</strong>  </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="541" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08143142/image-98-1024x541.png" alt="" class="wp-image-638402" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08143142/image-98-1024x541.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08143142/image-98-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08143142/image-98-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08143142/image-98.png 1208w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://editorial.benzinga.com/wp-admin/post.php?post=638401&amp;action=edit">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></strong></li>
</ul>


Earnings

CARG

CarGurus Analysts Boost Their Forecasts Following Better-Than-Expected Earnings

<p>Needham  analyst Joshua Reilly   maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and raises the price target from $525 to $600.</p>


AXON

Needham Maintains Buy on Axon Enterprise, Raises Price Target to $600

Quince Therapeutics (QNCX) has released an update. Quince Therapeutics, Inc. has enhanced its board by appointing Rajiv Patni as a Class III direct...

Quince Therapeutics Appoints Rajiv Patni to Board of Directors

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Quince Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/qncx-stock-quote/"><strong>QNCX</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Quince Therapeutics reported earnings per share of -21 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/qncx-stock-earnings-quince-therapeutics-for-q4-of-2023/">QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023

Quince Therapeutics GAAP EPS of -$0.26

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Quince Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/qncx-stock-quote/"><strong>QNCX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Quince Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/qncx-stock-earnings-quince-therapeutics-for-q1-of-2024/">QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024

Quince Therapeutics GAAP EPS of -$0.64

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Quince Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/qncx-stock-quote/"><strong>QNCX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Quince Therapeutics reported earnings per share of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/qncx-stock-earnings-quince-therapeutics-for-q2-of-2024/">QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

EF Hutton analyst Jason Kolbert initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $12 price target Quince is a biotechnology c...

Quince Therapeutics initiated with a Buy at EF Hutton

Rodman & Renshaw initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $11 price target Published first on TheFly – the ultimate s...

Quince Therapeutics initiated with a Buy at Rodman & Renshaw

QNCX

Press Releases

Quince Therapeutics Launches Scientific Advisory Board

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Comments

Quince Therapeutics

Quince Therapeutics (QNCX) Opzioni

Quince Therapeutics (NASDAQ:QNCX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO